Public Employees Retirement Association of Colorado Raises Stake in Charles River Laboratories International, Inc. $CRL

Public Employees Retirement Association of Colorado boosted its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 1,558.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 83,643 shares of the medical research company’s stock after buying an additional 78,600 shares during the quarter. Public Employees Retirement Association of Colorado’s holdings in Charles River Laboratories International were worth $16,685,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Tema Etfs LLC purchased a new stake in shares of Charles River Laboratories International during the fourth quarter valued at approximately $26,000. Rothschild Investment LLC raised its holdings in Charles River Laboratories International by 82.4% in the third quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock worth $29,000 after purchasing an additional 84 shares in the last quarter. Los Angeles Capital Management LLC bought a new position in Charles River Laboratories International in the fourth quarter worth $42,000. Sfam LLC bought a new position in Charles River Laboratories International in the fourth quarter worth $43,000. Finally, Activest Wealth Management raised its holdings in Charles River Laboratories International by 10,900.0% in the fourth quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock worth $44,000 after purchasing an additional 218 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Analyst Ratings Changes

CRL has been the subject of several analyst reports. Royal Bank Of Canada initiated coverage on Charles River Laboratories International in a report on Tuesday, April 14th. They set an “outperform” rating and a $215.00 price target for the company. Evercore reissued an “outperform” rating and issued a $220.00 target price on shares of Charles River Laboratories International in a research report on Friday, May 8th. Barclays raised their target price on Charles River Laboratories International from $210.00 to $220.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. CLSA raised Charles River Laboratories International from a “hold” rating to an “outperform” rating and raised their price objective for the stock from $167.00 to $219.00 in a research note on Friday, May 29th. Finally, UBS Group lifted their target price on Charles River Laboratories International from $170.00 to $175.00 and gave the company a “neutral” rating in a research note on Wednesday, February 25th. Eleven research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Charles River Laboratories International presently has an average rating of “Moderate Buy” and a consensus target price of $208.50.

Charles River Laboratories International Price Performance

CRL opened at $188.74 on Tuesday. The business has a fifty day moving average of $173.80 and a 200 day moving average of $182.57. Charles River Laboratories International, Inc. has a 52-week low of $143.06 and a 52-week high of $228.88. The company has a quick ratio of 1.03, a current ratio of 1.36 and a debt-to-equity ratio of 0.90. The stock has a market cap of $9.09 billion, a P/E ratio of -50.20, a PEG ratio of 2.14 and a beta of 1.46.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.96 by $0.10. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The company had revenue of $995.83 million during the quarter, compared to analysts’ expectations of $977.46 million. During the same quarter in the previous year, the business earned $2.34 EPS. Charles River Laboratories International’s revenue was up 1.2% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. As a group, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 11.04 EPS for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.